Immediate-release oxycodone for pain pharmacotherapy – when, to whom and why?

Ból ◽  
2021 ◽  
Vol 22 (2) ◽  
pp. 1-11
Author(s):  
Jarosław Woroń

Pharmacotherapy of pain must take into account the characteristics of pain, patient and drug in order to be optimally effective and safe. One of the drugs available on the pharmaceutical market is immediate-release oxycodone. The potential of this drug in practice is still not used. The paper describes clinical situations in which this form of the drug should be recommended for pain therapy.

2020 ◽  
pp. 16-28
Author(s):  
I. V. Zupanets ◽  
O. A. Ruban ◽  
O. M. Ievtushenko ◽  
Т. E. Kolisnyk

Chronic pain reduces patients’ life quality, affects their social and productive function in the state for a long period of time, or even for a whole lifetime. For the chronic pain treatment analgesic medications of symptomatic action are prescribed. According to international guidelines, paracetamol is one of the first line drugs. Aim – сonducting an assortment analysis of pharmaceutical medicines of Ukraine that can be used for the treatment of сhronic pain. Search for combined analgesics with hepatoprotective activity for the treatment of сhronic pain. Information sources: State Register of Medicines of Ukraine, Compendium web site. The analysis was conducted using content analysis and marketing research. Data processing and graphical analysis were performed in MS Excel software. During the marketing analysis of the registered in Ukraine medicines that can be used for mild and moderate сhronic pain treatment, the international non-proprietary names, listed in the national protocol of Ukraine, were selected. According to the ATC classification, these are groups N02B (non-narcotic analgesics) and M01A (non-steroidal anti-inflammatory and antirheumatic agents). N02B group has 245 registered drugs, 53.06% of which are produced domestically. Group M01A consists of 392 trade names that can be used for сhronic pain therapy. The ratio of Ukrainian manufacturers is only 39.80%, while foreign ones – 60.20%. For the treatment of сhronic pain tablet or capsule dosage forms are used. The market of analgesic products of Ukraine that can be used for сhronic pain therapy has been analyzed. It is established that the pharmaceutical market of Ukraine is import-dependent and promising for domestic enterprises. In Ukraine there are no drugs with paracetamol in combination with hepatoprotective ingredients and preparations directed exceptionally to сhronic pain treatment. In addition, there are practically no drugs of this direction in modern dosage forms (orally disintegrating tablets, soluble tablets, modified-release tablets, etc.) that improve patient compliance. All this is the basis for increasing the assortment of products in modern dosage forms.


2008 ◽  
Vol 24 (1) ◽  
pp. 22-26 ◽  
Author(s):  
Brian E. McGuire ◽  
Michael J. Hogan ◽  
Todd G. Morrison

Abstract. Objective: To factor analyze the Pain Patient Profile questionnaire (P3; Tollison & Langley, 1995 ), a self-report measure of emotional distress in respondents with chronic pain. Method: An unweighted least squares factor analysis with oblique rotation was conducted on the P3 scores of 160 pain patients to look for evidence of three distinct factors (i.e., Depression, Anxiety, and Somatization). Results: Fit indices suggested that three distinct factors, accounting for 32.1%, 7.0%, and 5.5% of the shared variance, provided an adequate representation of the data. However, inspection of item groupings revealed that this structure did not map onto the Depression, Anxiety, and Somatization division purportedly represented by the P3. Further, when the analysis was re-run, eliminating items that failed to meet salience criteria, a two-factor solution emerged, with Factor 1 representing a mixture of Depression and Anxiety items and Factor 2 denoting Somatization. Each of these factors correlated significantly with a subsample's assessment of pain intensity. Conclusion: Results were not congruent with the P3's suggested tripartite model of pain experience and indicate that modifications to the scale may be required.


2018 ◽  
Vol 12 (02) ◽  
pp. 155-165
Author(s):  
Holger Hendrix ◽  
Vladimir Kamlak ◽  
Georgi Prisadov ◽  
Katrin Welcker

The treatment of pain after thoracic surgery is a challenge and takes place in the individual clinics mostly according to clinic internal standards. It exists no currently valid S3 guideline for the treatment of acute perioperative and posttraumatic pain. For an effective pain treatment as well individual pain experience as the pain intensity of the various thoracic surgical procedures must be considered. Regular pain assessment with appropriate methods and their documentation form the basis for adequate and adapted pain therapy.There are a number of different pain therapy methods, non-medicamentous and drug-based methods, whose effectiveness is described in the literature partially different. For the treatment of acute postoperative pain after thoracic surgery, mainly drug-related procedures are used, except for physiotherapy as a non-medicamentous method. Increasingly, alternative procedures for the peridural catheter as a therapeutic gold standard in the treatment of pain after thoracic surgery are used. Their application can be integrated into a therapeutic algorithm.


Sign in / Sign up

Export Citation Format

Share Document